Amlodipiini ja benazepriili hydrochloride -kapselit on merkitty käyttöön verenpainetaudin hoitoon potilailla, joita ei ole saatu riittävästi hallintaan yksinään. Yhdistelmä hyödyntää amlodipiinia, dihydropyridinekaliumkanavanblokkaattoria, ja benazepriilia, entsyyminmuunnosentsyymin estäjää. Clinical studies involving over 950 patients demonstrated that once-daily doses of amlodipine and benazepril hydrochloride (using benazepril doses of 10 to 20 mg and amlodipine doses of 2.5 to 10 mg) decreased seated pressure (systolic/diastolic) by approximately 10 to 25/6 to 13 mmHg, 24 hours after dosing. The antihypertensive effect was sustained for up to 56 weeks, with reductions in blood pressure generally achieved within 1 to 2 weeks. The combination therapy was effective in both black and non-black patients. In nonblack patients, the blood pressure lowering effects were shown to be additive and in some cases synergistic. Within blacks, virtually all of the antihypertensive effect was attributed to the amlodipine component. Amlodipine inhibits calcium ion influx into vascular smooth muscle, while benazepril inhibits ACE, reducing angiotensin II levels and aldosterone secretion. During chronic therapy, serum potassium may increase up to 0.2 mEq/L. The usual starting dose is 2.5 mg of amlodipine and 10 mg of benazepril, administered orally once daily. Dosing is individualized, with titration up to 10 mg of amlodipine and 40 mg of benazepril possible if blood pressure remains uncontrolled. Abrupt withdrawal of the combination does not result in a rapid increase in blood pressure.